



With many thanks to the authors of this presentation

(which was created years ago, but is still up to date and very helpful)

Karina Dahl Steffensen Icó Tóth & Simona Ene




Sept 29 - Oct 1, 2023, Istanbul, Türkiye



How to create and submit an abstract

for the Patient Advocacy Seminar at the ESGO Congress

Authors: Karina Dahl Steffensen, Icó Tóth and Simona Ene



- \checkmark What is an abstract + example
- $\checkmark\,$ How to write an abstract
 - Title
 - Introduction (Background)
 - Methodology
 - Results
 - Conclusions
- $\checkmark\,$ How to submit an abstract
- ✓ Acceptance of the abstract



What is an abstract?

- ✓ Getting your paper accepted for any academic conference will involve writing an abstract.
- \checkmark Usually the abstract needs to be submitted many months ahead of the conference.
- An abstract is a brief summary of your research/initiative that is intended to capture the interest of a potential reader of your work. Thus in a sense it is a marketing document for your full presentation. Thus the first rule of abstract writing is that it should engage the reader by telling him or her what your work is about and why they should come to hear it.
- ✓ Usually the topic of the abstract presents data/findings from finished research or initiatives but could also be around ongoing projects or future plans.



An example of an abstract

The abstract shown here is a classic research abstract of the kind that health care professionals usually submit for conferences or as a summary of a full research paper.

Cabazitaxel - a treatment option in recurrent platinum-resistant ovarian cancer

Background and Aims:

Treatment of recurrent platinum-resistant ovarian cancer remains challenging due to the development of chemo-resistance. Cabazitaxel is a new taxane that has demonstrated effect in prostatic cancer patients resistant to Docetaxel. Therefore, it could be anticipated that it might also have an effect on chemo-resistant ovarian cancer. The presented results originate from the protocol Cabazitaxel vs. Tocotrienol in patients with Recurrent Ovarian Cancer after failure of standard therapy - A phase 2 randomized open-label study. EudraCT number: 2015-002296-18. Tocotrienol failed to reach its primary endpoint at time of interim analysis and the protocol was continued for cabazitaxel only.

Methods:

Twenty six patients with chemotherapy-resistant epithelial ovarian cancer, fallopian tubal or peritoneal cancer were treated with cabazitaxel at a dose of 25 mg/m2, day 1 q3w, until progression or inacceptable toxicity in the period from September 2015 – April 2018. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was prescribed to all patients. Two patients are still receiving treatment with cabazitaxel.

Results:

At time of referral for cabazitaxel treatment, patients had received a median of 3 previous chemotherapy regimens (range 2-8). The median number of cabazitaxel infusions was 4.0 (range 1-18). In general, cabazitaxel was well tolerated in patients with good performance status. In an intention- to- treat analysis, median PFS was 3.9 months (95% C.I; 1.9-5.2) using the combination of CA125 or RECIST (whichever came first). Median OS was 8.9 months (95% C.I; 7.0-10.9). The fraction of patients alive and without progression after three months of treatment was 13/26 patients (50%). Partial response (PR), evaluated by RECIST, was seen in 4/26 patients (15%). The response was confirmed by another scan in 3/26 patients (11.5%). A response rate of 46% (12/26) was detected according to the GCIG CA125 criteria.

Conclusions:

Our data show that cabazitaxel holds promise as a new drug in ovarian cancer. In general the toxicity was manageable.

An example of an abstract



The abstract shown here is an abstract from a patient advocacy group (it contains more than 300 words!)

Title: Extended hand

Mallowflower and Gynecologists for Cervical Cancer Medicine and Prevention

Speaker: Icó Tóth, Mallowflower Foundation, Dr. and Dr. Tünde Bartha, obstetrician-gynecologist, Mallowflower Foundation Board member

Key words: cervical cancer prevention, patient organization, linkage, cooperate

Introduction:

The Mallowflower Foundation is the first and still the only Hungarian NGO to promote the healing of cervical cancer women, to significantly improve their quality of life and to raise awareness of the importance of prevention among healthy women.

Our vision is not to lose a single woman because of cervical cancer in Hungary!

From 2015, we also help those affected by ovarian cancer, focusing on early detection.

The Mallowflower Foundation has now become a link between the public, stakeholders, professional organizations, the media and the authority.

Background:

cervical cancer incidens 1200 women cervical cancer mortality 450 women patient organization can help to reach the goals patient organization and experts need to work together, so far it didn't work well

Methodology:

Mallowflower Foundation want to introduce itself and offer its help.

We invite the gynecologist profession to work together for a future consensus meeting, where we determine what common goals are in the area of cervical cancer, what timeframe, who, and what will we do together.

We see that the incidence of cervical cancer in Hungary is stagnant. In order for this to change, you have to come across all the pages that affect the topic. The first step is to get to know each other's work and strengths and then build a common plan to have a visible result!

Result:

Collaboration

Without Cervical Cancer Hungary

There is a need for a lot of reconciliation to bring about a significant change in the domestic health situation, which is sad in international comparison. That's why we have launched the Mallowflower Movement in order to achieve the following goals together:

• The number of cervical cancer patients in Hungary will be significantly reduced,

- at least 50-70% of adult women should be screened annually
- consider more women and men as vaccine as a preventive option
- a rehabilitation program for patients
- be aware of the alternatives of prevention, healers and advanced patients with treatment options.

How to write an abstract? General information

- ✓ The abstract text may not be longer than 300 words (excluding title and disclosures).
- ✓ How to check words in Microsoft Office Word: Please go to <u>https://support.office.com/en-ie/article/video-show-word-count-in-documents-ab3fdbda-e994-4ff1-9b8a-a8bc81569e05</u>
- ✓ All abbreviations must be defined the first time they appear in your text (but, do not define in the title).
- Tables (maximum 2), charts and other graphics (maximum 2) are permitted and must be in JPG format, high resolution.
- ✓ Before submitting the abstract you need to contact all your co-authors they need to read the abstract, comment on it and agree on the submission for the conference.

How to write an abstract? Overview

- \checkmark Please send your abstract as an attachment to your e-mail.
- \checkmark Please follow this structure of the abstract:
 - Title*
 - Introduction/Background*
 - Methodology (if applicable)
 - Results*
 - Conclusions*
 - Disclosures*
- ✓ In the following the abstract structure and subheadings will be explained in more detail.

*Mandatory fields

How to write an abstract? **Title**



- ✓ Provide a short specific title indicating the nature of your work/project/campaign/research.
- ✓ The title of the proposed paper is important. Short attention-catching titles are the most effective. However, it is also important, for a conference abstract, to ensure that the title describes the subject you are writing about. It would be good if you can limit the length of the title to no more than 12 words.
- ✓ The **title** may not exceed **50 words** (ESGO requirement)

How to write an abstract? Introduction/Background



- ✓ The background and goals of the work/campaign/project study should appear clearly to the reader.
- \checkmark Why is it important and what is already known.
- ✓ You need to make a clear statement of the topic of your paper and why this work/initiative was launched (the aim).

How to write an abstract? Methodology



- \checkmark You need to say how your research was/is being undertaken.
- ✓ How was/is the project carried out?
- ✓ What initiatives?
- ✓ Did/will you measure something and what did/will you measure and how did/will you measure it?

How to write an abstract? **Results**



- \checkmark The methods and results usually contain data or some kind of findings.
- ✓ What did you learn?
- \checkmark What did you find and which value are your findings?
- ✓ Data examples: The number of patients participating or the number of visitors, media outreach etc.

How to write an abstract? **Conclusions**



- \checkmark The conclusion should be clearly expressed and short (a few lines).
- ✓ To whom will your study/initiative be of use?
- ✓ How will you use your results for future projects?

How to write an abstract? **Disclosures**




- Disclosure of potential conflict of interest (e.g. grant support, consultancy, membership on advisory councils, speaker's bureau) by all authors and source of funding are mandatory. Each listed author should prepare a one sentence statement that will be published with the abstract. All disclosures should be listed within the last 3 years.
- ✓ Abstracts from commercial entities will be considered. However, abstracts reporting results from collaborative research conducted by independent (non-company) investigators and investigators who are employees of commercial entities will not be accepted unless the independent (academic, clinician and/or scientist) investigators are included as authors.

How to write an abstract? Think about

- Before submitting the abstract it is a good idea to have someone fluent in English to proofread the abstract.
- ✓ When submitting the abstract you need full names, emails and affiliations for all your co-authors so please collect these data before sending the abstract.

Submitting an abstract

When you have finished writing, editing and proofreading your abstract, please send your abstract by e-mail before the deadline to: <u>engage@esgo.org</u> and write to the subject of the e-mail: **Abstract for PAS 2023.**




✓ Notification


Each abstract will be reviewed by a committee and final selection will be made by this committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email in July **2023**. Full instructions concerning preparation and presentation will be included.

✓ Publication

All accepted abstracts will be published on the ESGO Congress website and on ENGAGe website.



- You will receive a notification by email in August whether your abstract has been accepted by the ENGAGe committee.
- If accepted your next step will be to prepare, print and bring a Poster presentation (poster to hang) to Istanbul.



 If you have questions regarding abstracts or need any information about the Patient Advocacy Seminar Programme and Registrations, please contact us at: engage@esgo.org



engage@esgo.org
engage.esgo.org



20